STAT+: In China, a flood of controversial clinical trials slows to a trickle
Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.